The SunRISe-2 trial evaluating TAR-200 combined with cetrelimab vs chemoradiation in muscle-invasive bladder cancer has been ...

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price ...

Analysis by Macmillan estimates that around 60,000 women diagnosed with cancer under the age of 50 are struggling with ...

"Johnson & Johnson discontinues Phase III study of treatment for bladder cancer" was originally created and published by ...

Prostate cancer treatment can be lifesaving, but it can also cause many side effects. Learn how you can manage them.

J&J acquired rights to the silicone-based drug delivery service used in TAR-200, which allows for the continuous release of ...

The University is part of a nationwide team launching a new platform to understand immunotherapy response and side effects in ...

Johnson & Johnson said on Monday it has discontinued a late-stage study testing its experimental drug to treat a type of ...

Johnson & Johnson (JNJ) has discontinued a Phase 2 study of its drug TAR-200 for the treatment of muscle-invasive bladder ...

Researchers are a step closer to revolutionizing how doctors use radiotherapy to treat patients with muscle-invasive bladder ...

I’ve recently started on chemotherapy pills instead of infusions and the bitterness reminds me to accept not only the ...

A blood test, performed when metastatic prostate cancer is first diagnosed, can predict which patients are likely to respond to treatment and survive the longest. It can help providers decide which ...